Those 18 genes are PLEKHH1, TTC39A, ATP6V0D2, CENPE, KIF20A, ASPM, CKAP2L, HMMR, ECT2, TOP2A, KIF18B, TPX2, NUF2, TRIM59, FRZB, E2F8, TREM2, and MTHFD1L. Additionally, 7 downregulated PCK1, TSC22D3, SLC22A7, CYP2U1, SARDH, TTC36, and APOC1 were related to a worse overall survival rate in HCC patients suggesting their tumor suppressive effects. This evidence concerns the gene SARDH and neoplasm.